Non-steroidal anti-inflammatory drugs and CYP2C9 – Impacts of genetics and phenoconversion on the risk of adverse effects

Chronic pain affects over a quarter of Canadians and remains a leading cause of outpatient visits. It is prevalent in both adults and children, often persisting into adulthood, and imposes a significant economic burden exceeding $40 billion annually. Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain management as a safer alternative to opioids. However, the safety and efficacy of NSAIDs are influenced by genetic factors, particularly cytochrome P450 (CYP) polymorphisms,…

via https://pubmed.ncbi.nlm.nih.gov/42580545/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1HYeX0emtvYgH07Wkz0a8n9otrdMd-JIklc_uo0I5vh1u9WMEy&fc=None&ff=20260812010805&v=2.20.1


Post a Comment

Your email is never published nor shared. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>